Small Molecules

21 Sep 2020 Lynparza reduced the risk of death by 31% in BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in PROfound Phase III trial
21 Sep 2020 Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer
21 Sep 2020 Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
21 Sep 2020 Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer
20 Sep 2020 Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
20 Sep 2020 Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
20 Sep 2020 Orfadin® (nitisinone) receives positive opinion from CHMP for treatment of AKU
20 Sep 2020 Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors
20 Sep 2020 CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
20 Sep 2020 Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020 Virtual Annual Congress
20 Sep 2020 LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo
20 Sep 2020 TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
18 Sep 2020 Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease
18 Sep 2020 eXIthera Announces Publication of EP-7041 Data Demonstrating Safe Antithrombotic Activity in ECMO
18 Sep 2020 Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
18 Sep 2020 Boehringer Ingelheim and Mirati Therapeutics announce clinical collaboration to study BI 1701963, a SOS1::Pan-KRAS inhibitor in combination with MRTX849, a KRAS G12C selective inhibitor
18 Sep 2020 AstraZeneca acquires oral PCSK9 inhibitor programme from Dogma Therapeutics
18 Sep 2020 Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo
18 Sep 2020 Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer
17 Sep 2020 Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
17 Sep 2020 Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
16 Sep 2020 Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
16 Sep 2020 Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research
16 Sep 2020 CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease
16 Sep 2020 Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up